Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBijal ShahSCSwetha ChallagullaSXSheng Xu

Discussion

Loading...

Member takes

Overview

Indirect treatment comparison reveals zanubrutinib improves progression-free survival and overall survival versus acalabrutinib in relapsed/refractory mantle cell lymphoma.

Key Points

  • Zanubrutinib treatment is associated with significantly improved progression-free survival, with a hazard ratio of 0.57.
  • The overall survival for zanubrutinib also shows significant improvement, with a hazard ratio of 0.43.
  • An indirect treatment comparison was performed using a simulated treatment comparison method to evaluate the two drugs.
  • Results provide insights into the comparative efficacy of zanubrutinib and acalabrutinib for managing relapsed/refractory mantle cell lymphoma.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/68c239e5b210217d6477e1d7https://doi.org/10.1080/10428194.2025.2541911
View Full Paper
Ask AI
Bookmark
Share